Erratum to: Influenza A viruses: why focusing on M2e-based universal vaccines

Seyyed Mahmoud Ebrahimi · Majid Tebianian

Published online: 18 March 2011
© Springer Science+Business Media, LLC 2011

Erratum to: Virus Genes DOI 10.1007/s11262-010-0547-7

Unfortunately the paper published with an error in its content. Words “C57BL/6” and “100 LD90” must be changed to “Balb/c” and “LD90” respectively in lines 11, 16 and 17 of the second paragraph, right column of the 6th page of the article. The paragraph begun with “Recently, our scientific group in Razi vaccine and serum research institute....”,

Corrected text is given below:

Recently, our scientific group in Razi vaccine and serum research institute, RVSRI (Tehran, Iran) has started basic and experimental studies on the influenza A virus M2e protein as a candidate for universal influenza vaccine in the forms of recombinant full length M2 protein [75, 76], recombinant fusion protein, designated M2e-HSP70_{359–610} [47, 48, 77], DNA vaccine (Ebrahimi et al., unpublished

data), and VLPs (Ebrahimi et al., unpublished data). Accordingly, the relevant preclinical studies of recombinants M2e-HSP70_{359–610} fusion protein and full length M2 protein in Balb/c mice showed that linkage of M2e to C-terminal 28-kDa domain of *Mycobacterium tuberculosis* heat shock protein 70 (HSP70_{359–610}) significantly increased the potency of this vaccine candidate based on M2e-HSP70 fusion protein (SME-FLU-A) and fully protected (100%) vaccinated mice (Balb/c) from lethal challenge (LD90) of mouse-adapted influenza A virus, A/PR8/34 (H1N1), by significant inducing of M2e-specific antibody compared to the control groups of mice immunized with the recombinant full length M2 protein [75], *influvac*® vaccine 2009/2010 (Solvay, Netherlands), inactivated influenza vaccine 2009/2010 (Split Virion) BP (Sanofi Pasteur MSD, UK), and PBS with the survival rates of 10, 40, 15, and 0%; respectively (Ebrahimi et al., unpublished data).

The online version of the original article can be found under doi:[10.1007/s11262-010-0547-7](https://doi.org/10.1007/s11262-010-0547-7).

S. M. Ebrahimi (✉) · M. Tebianian
Department of Biotechnology, Razi Vaccine and Serum
Research Institute (RVSRI), P.O. Box 31975/148, Karaj,
Tehran, Iran
e-mail: smebrahimi@shirazu.ac.ir; sm.ebrahimi@rvsri.ir